Your browser is no longer supported. Please, upgrade your browser.
AVRO AVROBIO, Inc. daily Stock Chart
AVRO [NASD]
AVROBIO, Inc.
Index- P/E- EPS (ttm)-2.62 Insider Own1.90% Shs Outstand30.15M Perf Week-15.42%
Market Cap686.21M Forward P/E- EPS next Y-2.72 Insider Trans-13.50% Shs Float30.15M Perf Month2.11%
Income-66.30M PEG- EPS next Q-0.59 Inst Own97.70% Short Float3.18% Perf Quarter72.16%
Sales- P/S- EPS this Y-143.20% Inst Trans1.42% Short Ratio3.39 Perf Half Y17.68%
Book/sh6.82 P/B3.34 EPS next Y-7.50% ROA-46.50% Target Price38.22 Perf Year51.63%
Cash/sh6.85 P/C3.32 EPS next 5Y- ROE-50.20% 52W Range12.67 - 29.32 Perf YTD13.07%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-23.12% Beta-
Dividend %- Quick Ratio21.60 Sales past 5Y- Gross Margin- 52W Low77.90% ATR2.26
Employees73 Current Ratio21.60 Sales Q/Q- Oper. Margin- RSI (14)49.64 Volatility6.44% 10.22%
OptionableYes Debt/Eq0.00 EPS Q/Q-16.00% Profit Margin- Rel Volume0.75 Prev Close22.76
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume282.38K Price22.54
Recom1.80 SMA20-1.33% SMA505.56% SMA20025.92% Volume154,948 Change-0.97%
Jun-27-19Initiated Mizuho Buy $28
Apr-05-19Initiated Janney Buy
Oct-10-18Initiated Guggenheim Buy
Oct-02-18Reiterated H.C. Wainwright Buy $47 → $40
Sep-17-18Initiated H.C. Wainwright Buy $47
Jul-16-18Initiated Wells Fargo Outperform $40
Jul-16-18Initiated Wedbush Outperform $38
Jul-16-18Initiated Morgan Stanley Overweight $37
Feb-18-20 04:01PM  AVROBIO Announces Closing of Underwritten Public Offering Business Wire -5.67%
Feb-12-20 10:08PM  AVROBIO Announces Pricing of Underwritten Public Offering of $100 Million of Common Stock Business Wire
04:01PM  AVROBIO Announces Proposed Public Offering of Common Stock Business Wire
Feb-11-20 07:23AM  The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Benzinga
Feb-10-20 04:01PM  AVROBIO Presents Positive Initial Data for its Investigational Cystinosis Program and Plato TM Platform, as well as Positive Data Out to 32 Months for its Ongoing Investigational Fabry Program Business Wire +9.62%
Feb-06-20 07:00AM  AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-04-20 07:00AM  AVROBIO Announces Clinical Data Presentation and Multiple Events at WORLDSymposium 2020 Business Wire +11.69%
Jan-14-20 07:00AM  AVROBIO Announces Clinical and Regulatory Progress for Gaucher Disease Program Business Wire
Jan-09-20 04:00PM  AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Dec-19-19 08:00AM  AVROBIO Announces First Patient Dosed Using plato Platform Business Wire
Dec-16-19 08:00AM  AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Dec-14-19 07:47PM  Is AVROBIO, Inc. (AVRO) Going to Burn These Hedge Funds? Insider Monkey
Nov-07-19 07:00AM  AVROBIO, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update Business Wire
Nov-06-19 02:31PM  AVROBIO, Inc. (AVRO): Are Hedge Funds Right About This Stock? Insider Monkey
Oct-24-19 07:00AM  AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVRRD02 for the Treatment of Gaucher Disease Business Wire
Oct-22-19 07:00AM  AVROBIO Appoints Holly May as Chief Commercial Officer Business Wire
Oct-16-19 06:02AM  Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation Simply Wall St.
Oct-08-19 07:00AM  AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis Business Wire
Oct-03-19 08:00AM  AVROBIO, Inc. to Present at Chardans 3rd Annual Genetic Medicines Conference Business Wire
Sep-27-19 09:00AM  AVROBIO, Inc. (AVRO) Upgraded to Buy: Here's What You Should Know Zacks -5.53%
Sep-11-19 10:22AM  Moving Average Crossover Alert: AVROBIO Zacks
Aug-29-19 07:00AM  AVROBIO, Inc. to Present at Upcoming Investor Conferences Business Wire
Aug-16-19 08:30AM  AVROBIO Appoints Georgette Verdin as Chief Human Resources Officer Business Wire
Aug-12-19 05:36PM  AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-08-19 07:00AM  AVROBIO Reports Second Quarter 2019 Financial Results and Provides Business Update Business Wire +11.83%
04:02AM  3 Strong Buy Healthcare Stocks Insiders Are Buying Now TipRanks
Aug-06-19 08:00AM  AVROBIO, Inc. to Present at the 2019 Wedbush PacGrow Healthcare Conference Business Wire
Jul-29-19 08:08AM  3 Biotech Stocks Corporate Insiders are Buying TipRanks
Jul-26-19 07:51AM  Will AVROBIO Continue to Surge Higher? Zacks
Jul-19-19 04:01PM  AVROBIO Announces Closing of Underwritten Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire -6.19%
Jul-18-19 05:57AM  Did Changing Sentiment Drive AVROBIO's (NASDAQ:AVRO) Share Price Down By 34%? Simply Wall St.
Jul-17-19 04:26PM  Why Seattle Genetics, AVROBIO, and First Majestic Silver Jumped Today Motley Fool +19.52%
12:35PM  Here's Why Avrobio Rose as Much as 19.9% Today Motley Fool
Jul-16-19 09:58PM  AVROBIO Announces Pricing of Underwritten Public Offering of $120.25 Million of Common Stock Business Wire +16.69%
04:01PM  AVROBIO Announces Proposed Public Offering of Common Stock Business Wire
Jul-15-19 04:28PM  Why Crocs, Golden Star Resources, and AVROBIO Jumped Today Motley Fool +14.99%
07:00AM  AVROBIO Announces 87% Substrate Reduction in First Kidney Biopsy and Additional Positive Data from Clinical Trials of AVR-RD-01 Investigational Gene Therapy in Fabry Disease Business Wire
May-13-19 07:00AM  AVROBIO, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update Business Wire
May-12-19 06:43PM  Heres What Hedge Funds Think About AVROBIO, Inc. (AVRO) Insider Monkey
Apr-29-19 07:00AM  AVROBIO, Inc. Announces FDA Clearance of Investigational New Drug Application for AVR-RD-01 Gene Therapy for the Treatment of Fabry Disease Business Wire
Apr-26-19 04:00PM  AVROBIO Highlights the plato Platform and Gaucher and Cystinosis Programs at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy Business Wire
Mar-25-19 07:00AM  AVROBIO, Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update Business Wire
Mar-05-19 07:00AM  AVROBIO, Inc. to Present at the Cowen and Company 39th Annual Health Care Conference Business Wire -6.07%
Feb-06-19 09:00AM  AVROBIO, Inc. Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry Disease Business Wire
Feb-05-19 02:48PM  Investors Are Undervaluing AVROBIO, Inc. (NASDAQ:AVRO) By 46.82% Simply Wall St. +10.60%
Feb-01-19 07:00AM  AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019 GlobeNewswire +7.70%
Jan-18-19 07:43AM  AVROBIO Enters Oversold Territory Zacks +5.86%
07:00AM  AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis GlobeNewswire
Jan-17-19 07:00AM  AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019 GlobeNewswire -7.88%
Jan-07-19 07:06AM  AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors GlobeNewswire -5.62%
Dec-21-18 10:00AM  AVROBIO, Inc. Added to NASDAQ Biotechnology Index GlobeNewswire -12.12%
12:41AM  Should You Avoid AVROBIO, Inc. (AVRO)? Insider Monkey
Dec-19-18 07:00AM  AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR RD 01 for the Treatment of Fabry Disease GlobeNewswire -7.88%
Dec-18-18 07:05AM  AVROBIO, Inc. Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
07:00AM  AVROBIO, Inc. Expands and Strengthens Leadership Team with Four Senior Management Hires GlobeNewswire
Nov-28-18 01:05PM  Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns' Benzinga
Nov-21-18 07:35AM  Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +9.16%
Nov-13-18 08:00AM  AVROBIO, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire +5.79%
Oct-04-18 04:01PM  AVROBIO, Inc. to Present at Chardan's 2nd Annual Genetic Medicines Conference GlobeNewswire
Oct-01-18 07:01AM  AVROBIO Receives No Objection to Clinical Trial Application from Health Canada for AVR-RD-02 Gene Therapy for Gaucher Disease GlobeNewswire -51.55%
07:00AM  AVROBIO Announces Updated Clinical Data for AVR-RD-01 Gene Therapy in Fabry Disease GlobeNewswire
Aug-09-18 08:00AM  AVROBIO, Inc. Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Aug-08-18 08:00AM  AVROBIO, Inc. to Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-16-18 10:52AM  Newly Public Gene Therapy Biotech Avrobio Picks Up 2 Sell-Side Bulls Benzinga
Jun-27-18 08:00AM  AVROBIO, Inc. Appoints Phillip B. Donenberg to its Board of Directors GlobeNewswire
Jun-25-18 04:30PM  AVROBIO, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Overallotment Option GlobeNewswire
Jun-22-18 08:13PM  [$$] Five Drug Startups Reveal Plans to Join Blitz of Biotech IPOs The Wall Street Journal
Jun-21-18 11:41AM  [$$] Banner Day for Biotech as Five Drug Developers Go Public The Wall Street Journal
Jun-20-18 10:01PM  [$$] Eidos Therapeutics Goes Public, Joining Biotech IPO Flurry The Wall Street Journal
08:42PM  AVROBIO, Inc. Announces Pricing of Initial Public Offering GlobeNewswire
03:11PM  8 Biotech Stocks With IPOs This Week InvestorPlace
AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MACKAY GEOFFREYSee RemarksFeb 12Sale29.071,40040,692345,123Feb 14 07:16 PM
PAIGE CHRISTOPHERDirectorFeb 11Sale28.0015,000420,000252,512Feb 11 09:26 PM
MACKAY GEOFFREYSee RemarksFeb 11Sale27.5763,0001,737,081346,523Feb 11 09:23 PM
PAIGE CHRISTOPHERDirectorJan 28Sale23.0010,000230,000267,512Jan 30 04:10 PM